BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Information Letter on Dacogen 50 mg, powder for concentrate for solution for infusion: Changes regarding instructions for reconstitution and shelf life

2015.07.10

Active substance: decitabine

The company Janssen-Cilag GmbH is circulating information on measures to improve stability for reconstitution and shelf life of Dacogen.

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN PDF, 555KB, File is accessible